These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 137772)
1. Comparative physiologic dispositions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil in mice bearing solid L1210 lymphocytic leukemia. Chadwick M; Chang C Cancer Treat Rep; 1976 Jul; 60(7):845-55. PubMed ID: 137772 [TBL] [Abstract][Full Text] [Related]
2. Assay of intracellular free and macromolecular-bound metabolites of 5-fluorodeoxyuridine and 5-fluorouracil. Washtien WL; Santi DV Cancer Res; 1979 Sep; 39(9):3397-404. PubMed ID: 157805 [TBL] [Abstract][Full Text] [Related]
3. The physiological disposition of 5-fluorouracil in mice bearing solid L1210 lymphocytic leukemia. Chadwick M; Rogers WI Cancer Res; 1972 May; 32(5):1045-56. PubMed ID: 4259631 [No Abstract] [Full Text] [Related]
4. Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors. Garibjanian BT; Johnson RK; Kline I; Vadlamudi S; Gang M; Venditti JM; Goldin A Cancer Treat Rep; 1976 Sep; 60(9):1347-61. PubMed ID: 797450 [TBL] [Abstract][Full Text] [Related]
5. Pulmonary elimination and metabolism of 5-fluoro-2'-deoxyuridine in isolated perfused rat lung and lung slices. Foth H; Hellkamp J; Kunellis EM; Kahl GF Drug Metab Dispos; 1990; 18(6):1011-7. PubMed ID: 1981506 [TBL] [Abstract][Full Text] [Related]
6. Tumor-selective metabolism of 5-fluoro-2'-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil in mice bearing Lewis lung carcinoma. Boothman DA; Briggle TV; Greer S Cancer Res; 1987 May; 47(9):2354-62. PubMed ID: 2952263 [TBL] [Abstract][Full Text] [Related]
7. Simultaneous quantification of 5-FU, 5-FUrd, 5-FdUrd, 5-FdUMP, dUMP and TMP in cultured cell models by LC-MS/MS. Carli D; Honorat M; Cohen S; Megherbi M; Vignal B; Dumontet C; Payen L; Guitton J J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Oct; 877(27):2937-44. PubMed ID: 19620028 [TBL] [Abstract][Full Text] [Related]
8. Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil. Klubes P; Cerna I Cancer Res; 1983 Jul; 43(7):3182-6. PubMed ID: 6850628 [TBL] [Abstract][Full Text] [Related]
9. 5-fluorouracil and 5-fluoro-2'-deoxyuridine follow different metabolic pathways in the induction of cell lethality in L1210 leukaemia. Roobol C; De Dobbeleer GB; Bernheim JL Br J Cancer; 1984 Jun; 49(6):739-44. PubMed ID: 6234011 [TBL] [Abstract][Full Text] [Related]
10. Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells. Keyomarsi K; Moran RG Cancer Res; 1986 Oct; 46(10):5229-35. PubMed ID: 2944577 [TBL] [Abstract][Full Text] [Related]
11. Effect of deoxyuridine coadministration on toxicity and antitumor activity of fluorouracil and floxuridine. Jato JG; Lake LM; Grunden EE; Johnson BM J Pharm Sci; 1975 Jun; 64(6):943-6. PubMed ID: 124347 [TBL] [Abstract][Full Text] [Related]
12. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653 [TBL] [Abstract][Full Text] [Related]
13. Alteration of fluorouracil metabolism in human colon cancer cells by dipyridamole with a selective increase in fluorodeoxyuridine monophosphate levels. Grem JL; Fischer PH Cancer Res; 1986 Dec; 46(12 Pt 1):6191-9. PubMed ID: 2946402 [TBL] [Abstract][Full Text] [Related]
14. Potentiation by acyclothymidine esters of the antitumor effect of orally administered 5-fluoro-2'-deoxyuridine esters on L1210 in mice. Kawaguchi T; Saito M; Saneyoshi M Jpn J Cancer Res; 1986 May; 77(5):436-9. PubMed ID: 2942523 [TBL] [Abstract][Full Text] [Related]
15. Sequential methotrexate and 5-fluorouracil: mechanisms of synergy. Bertino JR; Mini E; Fernandes DJ Semin Oncol; 1983 Jun; 10(2 Suppl 2):2-5. PubMed ID: 6867754 [TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine. Cao S; McGuire JJ; Rustum YM Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100 [TBL] [Abstract][Full Text] [Related]
17. Rate-limiting steps in the interactions of fluoropyrimidines and methotrexate. Bowen D; Bailey BD; Guernsey LA Eur J Cancer Clin Oncol; 1984 May; 20(5):651-7. PubMed ID: 6234172 [TBL] [Abstract][Full Text] [Related]
18. Antitumor effect and tumor level of 5-fluoro-2'-deoxyuridylate following oral administration of tetradecyl 2'-deoxy-5-fluoro-5'-uridylate. Nakajima Y; Iigo M; Hoshi A Anticancer Drugs; 1992 Jun; 3(3):289-92. PubMed ID: 1525410 [TBL] [Abstract][Full Text] [Related]
19. Enzymatic conversion of 5-fluoro-2'-deoxyuridine to 5-fluorouracil or 5-fluoro-2'-deoxyuridine 5'-monophosphate in human tissues. Uchida M; Brown N; Ho DH Anticancer Res; 1990; 10(3):779-83. PubMed ID: 2142396 [TBL] [Abstract][Full Text] [Related]
20. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2'-deoxyuridine. Houghton JA; Houghton PJ; Wooten RS Cancer Res; 1979 Jul; 39(7 Pt 1):2406-13. PubMed ID: 156065 [No Abstract] [Full Text] [Related] [Next] [New Search]